Clinical Trials Logo

Kidney Insufficiency clinical trials

View clinical trials related to Kidney Insufficiency.

Filter by:

NCT ID: NCT06362759 Recruiting - Clinical trials for Chronic Kidney Diseases

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

TRANQUILITY
Start date: May 15, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney disease and elevated hs-CRP.

NCT ID: NCT05384899 Active, not recruiting - Covid19 Clinical Trials

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

Start date: June 15, 2021
Phase:
Study type: Observational

Since its inception, KPMP has developed sophisticated protocols for collection and analysis of human kidney tissue, and for collection of biofluids. Members of the consortium have wide-ranging expertise in conducting clinical studies, processing kidney tissue, advanced structural and molecular analysis and complex bioinformatics analysis, which will be used to leverage effectively as a group to better understand kidney disease. This joint protocol aims to synergize the COVID-19 study efforts of KPMP academic research centers, to collectively study COVID-19, including its renal presentation using kidney tissue and/or biofluids from patients suffering from COVID-19. This will increase the breadth and depth of data available to the public to expedite discoveries, identify therapeutics, and improve outcomes for patients with COVID-19. It will additionally bring the expertise of KPMP investigators to bear against this pandemic.

NCT ID: NCT04626427 Terminated - Clinical trials for Chronic Kidney Diseases

The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation

WAVE-Global
Start date: December 22, 2020
Phase: N/A
Study type: Interventional

This is a global, multi-center, prospective, post-market, confirmatory, interventional, non-randomized, single-arm clinical investigation evaluating arteriovenous fistula (AVF) creation by means of the WavelinQ™ EndoAVF System in patients who require a vascular access for hemodialysis (HD).

NCT ID: NCT04610593 Completed - Clinical trials for Chronic Kidney Diseases

Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis

Start date: May 6, 2019
Phase: N/A
Study type: Interventional

This project has as main objective to evaluate the effects of a Mindfulness-based intervention (MBI) in the reduction of stressors, pain and quality of life of people with chronic kidney disease undergoing hemodialysis (HD). The investigators hypothesize that this program offered during hemodialysis sessions may modify the pain profile, stressors levels and may improve the quality of life by the people in hemodialysis. This is an incipient field of research at the international level and almost nonexistent in Brazil. Evidence indicates the need for MBIs to be performed during HD sessions, adapted to the context, to facilitate patient compliance, contribute to the management of the discomfort generated during HD and promote health.

NCT ID: NCT04594161 Completed - Kidney Diseases Clinical Trials

Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis

STONE
Start date: July 15, 2020
Phase: N/A
Study type: Interventional

To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or kidney function deterioration) caused by urolithiasis.

NCT ID: NCT04485845 Recruiting - Metabolic Syndrome Clinical Trials

Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression

Start date: November 1, 2019
Phase: Phase 4
Study type: Interventional

Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD . Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin remain unclear, they extend well beyond glycemic lowering, and therefore are probably best considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes drugs. Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's purpose was to observe their effects on weight control, Cardiometabolic Risk Factors, Metabolic Syndrome risk, and diabetic nephrooathy Progression.

NCT ID: NCT04334707 Recruiting - Clinical trials for Chronic Kidney Diseases

Kidney Precision Medicine Project

KPMP
Start date: September 1, 2019
Phase:
Study type: Observational

Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despite significant effort from industry and academia, development of pharmacologic therapies for AKI and CKD has been hampered by: Non-predictive animal models The inability to identify and prioritize human targets The limited availability of human kidney biopsy tissue A poor understanding of AKI and CKD heterogeneity Historically, AKI and CKD have been described as single, uniform diseases. However, growing consensus suggests that different disease pathways lead to different subgroups of AKI and CKD (AKIs and CKDs). Access to human kidney biopsy tissue is a critical first step to define disease heterogeneity and determine the precise molecular pathways that will facilitate identification of specific drug targets and ultimately enable individualized care for people with AKI and CKD. A number of research centers across the United States are collaborating to bring state-of-the-art technologies together to: - Ethically obtain and evaluate kidney biopsies from participants with AKI or CKD - Define disease subgroups - Create a kidney tissue atlas - Identify critical cells, pathways, and targets for novel therapies The KPMP is made up of three distinct, but highly interactive, activity groups: - Recruitment Sites: The recruitment sites (RS) are responsible for recruiting participants with AKI or CKD into the longitudinal study and performing the kidney biopsy. - Tissue Interrogation Sites: The tissue interrogation sites (TIS) are responsible for developing and using innovative technologies to analyze the biopsy tissue. - Central Hub: The central hub is responsible for aggregating, analyzing, and visualizing the generated data and providing scientific, infrastructure, and administrative support for the KPMP consortium.

NCT ID: NCT04058951 Recruiting - Hypertension Clinical Trials

Plant Versus Animal Dietary Protein and the Effect on Proteinuria

NYPRO
Start date: August 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate if a diet high in plant protein improves kidney function in patients with kidney insufficiency and diabetes and/or hypertension and/or glomerulonephritis. The study is a non-blinded, randomized, controlled, cross-over-design with two intervention periods of each 14 days. Between the two interventions periods there is a washout period of 14 days. The participants are randomized to start with an individualized diet plan containing either high amounts of animal protein or high amounts of plant protein.

NCT ID: NCT03840343 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

Start date: October 23, 2019
Phase: Phase 1
Study type: Interventional

The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).

NCT ID: NCT02964429 Completed - Clinical trials for Kidney Insufficiency

Determination In-vivo KUF for Diacap Pro Hemodialyser

Start date: November 14, 2016
Phase: N/A
Study type: Interventional

The main purpose of this study is the determination of the in-vivo ultrafiltration coefficient (in-vivo KUF) for Diacap Pro dialyzers following routine dialysis prescription in the United States.